Position in TGTX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$14,164,309
-$4,614,349 QoQ
Shares Held
426,379
-32.3% QoQ
Ownership
0.279%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 7%
Shared 0%
None 93%
Common Shares in TGTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RAYMOND JAMES FINANCIAL INC holds $1,498,619,160 across 194 Biotechnology names. TGTX ranks #25 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
444,496 | $198,485,243 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
406,956 | $134,649,528 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
165,542 | $127,904,369 | |
| 4 | INSM |
INSMED Inc
|
775,148 | $126,752,197 | |
| 5 | RPRX |
Royalty Pharma plc
|
1,524,018 | $73,107,140 | |
| 6 | VKTX |
Viking Therapeutics, Inc.
|
2,075,403 | $67,533,612 | |
| 7 | EXEL |
Exelixis, Inc.
|
1,045,595 | $44,845,567 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
156,064 | $40,314,451 |
All Filings in TGTX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,164,309 | 426,379 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $18,778,658 | 629,945 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $24,352,836 | 674,127 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $24,428,498 | 678,758 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $27,092,351 | 687,100 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $14,507,867 | 481,989 | Shares | Defined | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||